New drug EVOLVE104 takes on tough cancers in early human trial
NCT ID NCT07217171
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for patients who have already tried standard treatments or cannot take them. About 160 participants will receive the drug by IV infusion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EVOLVE104 (an experimental drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for advanced bladder and squamous cell cancers that have not responded to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 160 participants, so the drug may not prove effective or safe enough for wider use. Side effects are unknown and could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Columbia University Irving Medical Center
RECRUITINGNew York, New York, 10032, United States
Contact Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Email: •••••@•••••
-
Memorial Sloan Kettering Cancer Center
RECRUITINGNew York, New York, 10065, United States
Contact Email: •••••@•••••
-
SCRI
RECRUITINGNashville, Tennessee, 37203, United States
Contact Email: •••••@•••••
-
START Midwest
RECRUITINGGrand Rapids, Michigan, 49546, United States
Contact Email: •••••@•••••
-
The Winship Cancer Institute Emory University
RECRUITINGAtlanta, Georgia, 30322, United States
Contact Email: •••••@•••••
-
Thomas Jefferson University, Sidney Kimmel Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19107, United States
Contact Email: •••••@•••••
-
USC/Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
Contact Email: •••••@•••••
-
Virginia Cancer Specialists
RECRUITINGFairfax, Virginia, 22031, United States
Contact Email: •••••@•••••
-
Yale University Cancer Center
RECRUITINGNew Haven, Connecticut, 06511, United States
Contact Email: •••••@•••••